How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Coetzer looks at advances in CRISPR-Cas9 genome editing as well as critical aspects that must be addressed and optimized before the technology can be implemented in a clinical setting to treat patients.
Dr. Coetzer discusses a study that looks at a therapeutic genome editing strategy where a benign naturally occurring mutation is repeated ex vivo in cells from SCD patients.
Dr. Coetzer talks about the discovery of SHP099, which represents an exciting breakthrough and a promising treatment approach for RTK-driven cancers.
Dr. Coetzer studies the functions of the tumor suppressor PTEN as a new strategy to overcome drug resistance in human pre-B acute lymphoblastic leukemia.
Dr. Coetzer reviews a study that looks at the molecular defect in a subset of CID patients and resulting enhanced expression of TfR1 on lymphocytes, which has clinical relevance as it could be a useful diagnostic tool.
Dr. Coetzer discusses the N-PhenoGENICS trial and calls for new research to answer questions about secondary effects of chemotherapy in children.
Dr. Coetzer looks at advancements in the discovery of new therapies to treat malaria. She reviews four studies that show major developments in battling this pathogen and highlights several challenges that remain to ensure that current progress in this battle is not lost.
Dr. Coetzer discusses a study that provides insights into the potential of new drugs to treat CML.
Dr. Coetzer studies how malaria parasites invade human erythrocytes, and the possibility of using hematopoietic stem cell-based forward genetic screening approach to investigate host factors implicated in malaria pathogenesis.
Dr. Coetzer discusses a synthetic lethal approach to treating AML in patients with isocitrate dehydrogenase mutations, and the importance of a personalized approach to cancer chemotherapy.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology